Literature DB >> 1438026

Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis.

G Claesson1, M Eriksson, J D Rogers.   

Abstract

Fifteen children (3-12 years) with peritonitis were given imipenem/cilastatin intravenously (15 or 25 mg/kg) every six hours for 3-14 days. One day during treatment days 2-8, multiple blood and urine samples were collected from each individual over a six hour dosing interval. Twelve children completed the study. The urinary recovery of imipenem and cilastatin averaged 50-70% of the administered dose. The plasma t1/2 for imipenem averaged 55 min. while that for cilastatin was even more rapid (approximately 38 min.). Little or no accumulation of either imipenem or cilastatin was observed for this regimen in this age group of paediatric patients. Steady state conditions prevailed within 2 days of initiation of therapy. The pharmacokinetics of imipenem and cilastatin in paediatric patients 3-12 years of age appear similar to those observed for adults.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438026     DOI: 10.1111/j.1600-0773.1992.tb00527.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  3 in total

1.  Prospective determination of plasma imipenem concentrations in critically ill children.

Authors:  Eric Giannoni; Philippe Moreillon; Jacques Cotting; Adrien Moessinger; Jacques Bille; Laurent Décosterd; Giorgio Zanetti; Paul Majcherczyk; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 2.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

Review 3.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.